Thirty-five male patients ( aged 16-58 ) with a basal C-peptide greater than 0.1 nmol/L were assigned to periodic treatment with DiaPep277 ( 1 mg ) or placebo for a 12-month treatment and 18-month observation protocol , later extended to an additional year of treatment .
